Editing Alopecia areata (section)

== Research ==

Many medications are being studied.<ref>{{cite web|title=Search - clinicaltrials.gov for alopecia areata|url=https://clinicaltrials.gov/ct2/results?term=alopecia+areata&recr=Open&rslt=&type=&cond=&intr=&titles=&outc=&spons=&lead=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&rcv_s=&rcv_e=&lup_s=&lup_e=|website=clinicaltrials.gov|publisher=National Institutes of Health|access-date=5 April 2016|url-status = live|archive-url=https://web.archive.org/web/20170908192255/https://clinicaltrials.gov/ct2/results?term=alopecia+areata&recr=Open&rslt=&type=&cond=&intr=&titles=&outc=&spons=&lead=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&rcv_s=&rcv_e=&lup_s=&lup_e=|archive-date=8 September 2017}}</ref>

In 2014, preliminary findings showing that oral [[ruxolitinib]], a drug approved by the US [[Food and Drug Administration]] (FDA) for bone marrow disorder [[myelofibrosis]], restored hair growth in three individuals with long-standing and severe disease.<ref>{{cite journal | title = A ray of hope for alopecia areata patients | vauthors = Mohammadi D | journal = The Pharmaceutical Journal | volume = 296 | issue = 7889 | doi = 10.1211/PJ.2016.20201092 | year = 2016 }}</ref>

In March 2020, the US FDA granted [[breakthrough therapy]] designation to [[baricitinib]] for the systematic treatment of alopecia areata<ref>{{cite press release | title=Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata | publisher=Eli Lilly and Company | via=PR Newswire | date=16 March 2020 | url=https://www.prnewswire.com/news-releases/lilly-receives-fda-breakthrough-therapy-designation-for-baricitinib-for-the-treatment-of-alopecia-areata-301024437.html | access-date=16 March 2020 | archive-date=17 March 2020 | archive-url=https://web.archive.org/web/20200317170907/https://www.prnewswire.com/news-releases/lilly-receives-fda-breakthrough-therapy-designation-for-baricitinib-for-the-treatment-of-alopecia-areata-301024437.html | url-status=live }}</ref> and granted approval in June 2022,<ref name="Lilly PR 20220613" /> with a 32% efficacy rate for people with 50% hair loss reaching 80% scalp coverage in 36 weeks.<ref name="FDA PR 20220613">{{cite press release | title=FDA Approves First Systemic Treatment for Alopecia Areata | website=U.S. [[Food and Drug Administration]] (FDA) | date=13 June 2022 | url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-systemic-treatment-alopecia-areata | access-date=13 June 2022 | archive-date=14 June 2022 | archive-url=https://web.archive.org/web/20220614051142/https://www.fda.gov/news-events/press-announcements/fda-approves-first-systemic-treatment-alopecia-areata | url-status=live }} {{PD-notice}}</ref> It acts as an [[Janus kinase inhibitor|inhibitor of janus kinase]] (JAK), blocking the subtypes [[JAK1]] and [[JAK2]].<ref name="CHMP">{{cite web |title=Summary of opinion for Olumiant |publisher=[[European Medicines Agency]] (EMA) |date=15 December 2016 |url=http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004085/WC500218183.pdf |access-date=18 December 2016 |archive-date=15 March 2018 |archive-url=https://web.archive.org/web/20180315212105/http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004085/WC500218183.pdf |url-status=live }}</ref>